Bachem sees sales increase in 2013

Bachem has released its full-year results for 2013.

The report showed the peptide manufacturer generated sales of 170.7 million CHF (117.48 million pounds) in 2013, up from 157.3 million CHF in 2013.

Furthermore, although generics sales slightly fell short of expectations, the business with patented substances – a bellwether of Bachem's future sales – experienced brisk growth.

Thomas Fruh, chief executive and chairman of the company's Corporate Executive Committee, said the success of the year had been due to the availability of a properly trained workforce of experienced and dedicated staff. 

"Intensive cooperation with the academic research community and the relevant professional associations enables Bachem to scout out budding new technologies and actively determine the shape of things to come," he added.

Going forward, Bachem said it will look to concentrate on its core business of peptides with focus on innovation and quality. Staff expertise and the ability to build close partnerships with customers will continue to be the key drivers of the company's future success.